Overview of Key Ozone Epidemiology Literature

Julie E. Goodman, Ph.D., DABT, ACE, ATS

Ozone Webinar Texas Commission on Environmental Quality March 20, 2015



Epidemiology

- The study of the causes, distribution, and control of disease in populations
- Realistic exposure conditions



- Doesn't require extrapolation of results from animals
- Sometimes sufficient to causation
- Individual studies may have limitations that can affect the interpretation of results



Types of Epidemiology Studies



Observational Studies

- Ecological
- Cluster analysis
- Case study/series
- Cross-sectional
- Case-control
- Cohort
- Panel
- Time-series
- Case-crossover



Experimental Studies

- Controlled exposure
- Clinical trial

Reviews


- Literature review
- Meta-analysis
- Weight-of-Evidence






Confounding

A **confounder** is a factor associated with both the exposure and the health outcome, but is not in the causal pathway of interest (*e.g., other exposures, age*)





Confounding Example






Dealing with Confounding

Design phase

- "Match" or restrict participants on potential confounders
- Collect information on potential confounders

Analysis phase

- Conduct stratified analysis
- Account for confounder in statistical model





Other Limitations in Ozone Epidemiology Studies

- Exposure measurement error central ambient monitoring sites provide community-wide averages
- Model misspecification
- Model selection bias
- Publication bias
- Heterogeneity






Heterogeneity

- Risks not statistically significant in vast majority of cities.
- "Protective" effects in some cities indicate causal association unlikely.
- Between-city heterogeneity remains unexplained

8-HOUR OZONE-MORTALITY COEFFICIENTS RAW ESTIMATES AND 95% CONFIDENCE INTERVALS



Smith et al. (2009)

Ozone Epidemiology Study Designs

- Short-term exposure (hours, days, or weeks)
 - Time-series studies
 - Case-crossover studies
 - Panel studies
- Long-term exposure (months, years)
 - Longitudinal cohort studies
- One time point
 - Cross-sectional studies





Time-series Studies

- Aggregate estimates of exposure and health
 - Central site monitors and existing databases
- **<u>Population-average</u>** rates of acute health events
 - Hospital admissions (HA), emergency department (ED) visits, death rates







Time-series Studies



Strengths

- Can assess health status in a large population over many years
- Efficient use of resources
- Captures temporal ozone concentration variability
- Insensitive to time-invariant subject characteristics
 - Smoking history
 - Socio-economic status

Limitations

- Confounding by time-varying factors
 - Temperature
 - Respiratory infection epidemics
 - Outdoor pollen and other aeroallergens
 - Temporal trends
- Ecological in nature
- Exposure measurement error



Case-crossover Studies


- Individual-level exposure estimates
 - Central site monitors often used
 - Case period vs. control period
- Individual-level acute health events
 - Administrative data often used: hospital admissions (HA), emergency department (ED) visits







Case-crossover Studies





Case-crossover Studies



Strengths

- Can use existing databases
- Can make individual-level causal inference
- Inherently controls for temporal trends
- Captures temporal ozone concentration variability
- Insensitive to time-invariant subject characteristics
 - Smoking history
 - Socio-economic status

Limitations

- Confounding by timevarying factors
 - Temperature
 - Respiratory infection epidemics
 - Outdoor pollen and other aeroallergens
 - Outdoor activities
- Exposure measurement error



Panel Studies

- Repeatedly assess health status of <u>individual subjects</u>
- Time-varying ozone exposure
 - Central-site monitoring or personal exposure
- Commonly used to investigate lung function and asthma symptoms





Panel Studies



Strengths


- Subjects serve as their own controls
- Individual-level outcome data
- Captures health outcomes that resolve in a short time frame

Limitations

- Self-reported outcomes (*e.g.*, symptoms, lung function)
- Challenging to account for missing data
- Compliance can be low
- Confounding by time-varying factors
 - Temperature
 - Respiratory infection epidemics
 - Outdoor pollen and other aeroallergens
 - Outdoor activities




Longitudinal Cohort Studies





Longitudinal Cohort Studies



Strengths

- Less bias in risk factor data
- Can evaluate several diseases
- Yields incidence rates and relative risks
- Can control for individuallevel characteristics

Limitations

- Large sample size, long follow-up period
- Problem with attrition
- Changes in methods and classifications over time
- Costly
- Exposure measurement error
- Confounders
 - Measurement error
 - Proxy measures



Cross-sectional Studies

- Exposure status and disease status are measured at one point in time or over a short period. No follow-up.
- Comparison of disease prevalence among exposed and non-exposed (*e.g.*, asthma prevalence)





Cross-sectional Studies

Advantages

- Relatively inexpensive, little time to conduct
- Can look at many risk factors and outcomes
- Results often generalizable

Disadvantages

- Exposure and disease measured at same time
- Only see longer-lasting cases



Health Endpoints Evaluated in Ozone Studies

Short-term ozone exposure (hours, days, weeks)

- Respiratory effects
- Cardiovascular effects
- Mortality

Long-term ozone exposure (months, years)

- Respiratory effects
- Cardiovascular effects
- Reproductive and developmental effects
- Central nervous system effects
- Cancer
- Mortality



Strickland *et al.* (2010) – Pediatric Asthma or Wheeze ED Visits


Rate Ratios (95% CIs) for IQR Increases in 3-day Moving Average Ozone, Atlanta, Georgia (1993-2004)

	Warm Season (May-October)	Cold Season (November-April)
Base Model	1.082 (1.043–1.123)	1.044 (0.992–1.098)
No URI Control	1.106 (1.066–1.147)	1.062 (1.010–1.118)
Time-series	1.071 (1.025–1.119)	1.013 (0.953–1.077)
Case-crossover	1.092(1.049–1.137)	1.053 (0.996–1.113)
Bi-monthly windows	1.058 (1.014–1.104)	1.019 (0.961–1.113)
Lag -1 Pollution	1.015 (0.991–1.039)	1.004 (0.973–1.036)

Source: Table 4; Strickland, MJ; Darrow, LA; Klein, M; Flanders, WD; Sarnat, JA; Waller, LA; Sarnat, SE; Mulholland, JA; Tolbert, PE. 2010. "Short-term associations between ambient air pollutants and pediatric asthma emergency department visits." *Am. J. Respir. Crit. Care Med.* 182(3):307-316.




Mar and Koenig (2009) – Asthma ED Visits in Seattle, Washington



Risk assoc with 10 ppb max 1-hr avg ozone

Risk assoc with 10 ppb max 8-hr avg ozone



Mar, TF; Koenig, JQ. 2009. "Relationship between visits to emergency departments for asthma and ozone exposure in greater Seattle, Washington." *Ann. Allergy Asthma Immunol.* 103:474-479.



Katsouyanni *et al.* (2009) – Air Pollution and Health: A European and North American Approach

Association between all-cause mortality and 40 ppb increase in 1-hr max ozone			
Location	Percent Change	95% CI	
Europe	1.66	0.47-2.94	
Canada	5.87	1.82-9.81	
US	3.02	1.10-4.89	

Katsouyanni, K; Samet, JM; Anderson, HR; Atkinson, R; Le Tertre, A; Medina, S; Samoli, E; Touloumi, G; Burnett, RT; Krewski, D; Ramsay, T; Dominici, F; Peng, RD; Schwartz, J; Zanobetti, A. October 29, 2009. "Air Pollution and Health: A European and North American Approach (APHENA)." HEI Research Report 142. 132p. [209-6475]



Zanobetti and Schwartz (2008) – Short-term Ozone and Mortality




Figure 1. Effect of a 10-ppb increase in 8-hour ozone on mortality overall and by city, during the June-August months. The results are sorted by the confidence interval amplitude.

Zanobetti, A; Schwartz, J. 2008. "Mortality displacement in the association of ozone with mortality: An analysis of 48 cities in the United States." Am. J. Respir. Crit. Care Med. 177(2):184-189.


Cop

Jerrett *et al.* (2009) – Long-term Ozone Exposure and Respiratory Mortality

Relative risk (95% CI) of death due to 10-ppb change in ambient ozone conc.		
Cause of Death	Ozone and PM _{2.5}	
Any cause	0.989 (0.981, 0.996)	
Cardio-pulmonary	0.992 (0.982, 1.003)	
Respiratory	1.040 (1.013, 1.067)	
Cardiovascular	0.983 (0.971, 0.994)	
Ischemic Heart Disease	0.973 (0.958, 0.988)	



Jerrett *et al.* (2009) – Long-term Ozone Exposure and Respiratory Mortality



Jerrett, M; Burnett, RT; Pope, CA; Ito, K; Thurston, G; Krewski, D; Shi, Y; Calle, E; Thun, M. 2009. "Long-term ozone exposure and mortality." *N. Engl. J. Med.* 360(11):1085-1095.



Questions?

Julie E. Goodman, PhD, DABT, ACE, ATS Gradient jgoodman@gradientcorp.com

